Development of a novel DNA sequencing method not only for hepatitis B virus genotyping but also for drug resistant mutation detection.
BACKGROUND
In HBV-infected patients, different genotypes of the hepatitis B virus influence liver disease progression and response to antiviral therapy. Moreover, long-term antiviral therapy will eventually select for drug-resistant mutants. Detection of mutations associated to antiviral therapy and HBV genotyping are essential for monitoring treatment of chronic hepatitis B patients.


RESULTS
In this study, a simple method of partial-S gene sequencing using a common PCR amplification was established for genotyping clinical HBV isolates sensitively, which could detect the drug-resistant mutations successfully at the same time.


CONCLUSIONS
The partial S gene sequencing assay developed in this study has potential for application in HBV genotyping and drug resistant mutation detection. It is simpler and more convenient than traditional S gene sequencing, but has nearly the same sensitivity and specificity when compared to S gene sequencing.
State Key Laboratory of Virology and College of Life Sciences, Wuhan University, Wuhan 430072, PR China.
Fanjun
F
Wang
Lili
L
Lu
Changshun
C
Yu
Zhanwu
Z
Lv
Xuelian
X
Luo
Chao
C
Wan
Zhaohui
Z
Hu
Qinyi
Q
Zhu
Youping
Y
Deng
Chuyu
C
Zhang
D000998:Antiviral Agents / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D004279:DNA, Viral / Q000032:analysis*; D024882:Drug Resistance, Viral / Q000235:genetics; D016679:Genome, Viral; D005838:Genotype; D006514:Hepatitis B Surface Antigens / Q000737:chemistry / Q000235:genetics; D006515:Hepatitis B virus / Q000145:classification / Q000378:metabolism*; D019694:Hepatitis B, Chronic / Q000188:drug therapy; D006801:Humans; D009154:Mutation; D010802:Phylogeny
D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens